UCB, in­vestors back a neu­ro­sciences start­up called Syn­de­si; Ger­many's Biofron­tera in­creas­es US IPO pric­ing range

→ UCB and a syn­di­cate of Bel­gian and in­ter­na­tion­al in­vestors have joined hands to launch a new biotech called Syn­de­si Ther­a­peu­tics. The Bel­gian start­up gained a €17 mil­lion A round, which will be used to back a lead small mol­e­cule ob­tained from UCB’s neu­ro­science group, which has been study­ing a class of nov­el SV2A mod­u­la­tors. “We are ex­cit­ed to see Syn­de­si de­vel­op our nov­el pro-cog­ni­tive SV2A mod­u­la­tors to cre­ate val­ue for pa­tients with cog­ni­tive im­pair­ment,” said Dhavalku­mar Pa­tel, UCB’s CSO. The cash was put up by No­vo Seeds and Foun­tain Health­care to­geth­er with John­son & John­son In­no­va­tion – JJDC, V-BIO Ven­tures, the Wal­loon In­vest­ment Fund (SRIW) and VIVES Lou­vain Tech­nol­o­gy Fund.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER